Date: 2012-02-27

Type of information:

Compound: cancer biomarkers based on circulating tumour cells, optimization of Parsotix's device

Company: Parsortix (UK) The Paterson Institute for Cancer Research (UK)

Therapeutic area: Cancer Oncology

Type agreement: R&D

Action mechanism:

Disease: cancer


ANGLE has announced that Parsortix, its 90% owned portfolio company which specialises in cancer diagnostics, has signed a two year research agreement with the Cancer Research UK-funded Paterson Institute for Cancer Research, The University of Manchester’s world-leading cancer research institute.
ANGLE will be working with the Paterson Institute’s Clinical and Experimental Pharmacology Group (CEP), which specialises in circulating tumour cells (CTCs). The Parsortix CTC research at the Paterson will be led by CEP director Professor Caroline Dive and her deputy Dr Ged Brady.
The main areas of focus for the collaborative work will include:
• cancer patient blood studies to provide further independent confirmation of the performance of the Parsortix device and to optimise its design;
• development of research and clinical applications of the Parsortix device utilising cancer bio-markers;
• evaluation of the Parsortix cassette CTC capture characteristics in relation to other CTC technology platforms;
• in-depth comparative studies to support regulatory approval submissions by Parsortix for CE marking in Europe and FDA approval in the United States.

In addition to Parsortix’s focused in-house capability, outsourcing research and development activity provides ANGLE with cost-effective access to world class expertise, capability and facilities and provides the CEP group with new avenues to extend its CTC research.

Parsortix has developed a patented separation platform technology for the isolation of cells in blood, including rare cells which occur in very low numbers, such as one cell within 500 million other cells. Using this technology, cells can be differentiated from one another based on their size, shape, deformability, or a combination of these characteristics. The separation device successfully separates cancer cells added to healthy whole blood. This “spiked blood” separation is a pre-cursor to isolating cancer cells in cancer patient blood. Parsortix has been issued a U.S. Patent Number 7,993,908, entitled “Microstructure for Particle and Cell Separation, Identification, Sorting, and Manipulation”.


Financial terms:

Latest news:

Is general: Yes